Skip to main content

Table 4 Number of proliferating cells/HPF identified by Ki67 in the renal cortex and OSOM of different experimental groups

From: Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

  Group I Group II Group III Group IV Group V Group VI
negative control cisplatin ‘CDDP’-treated cisplatin + rBMSCs-treated cisplatin + hADSCs-treated (n = 20) cisplatin + hAFSCs-treated cisplatin + DMEM culture media-treated
Renal cortex
 Day 4 6.0 ± 1.58 8.6 ± 1.14 20.8 ± 2.77ab 18.8 ± 1.30ab 18.8 ± 3.34ab 8.4 ± 1.14cde
 Day 7 9.0 ± 1.58 13.8 ± 2.38 26.4 ± 3.05ab 17.8 ± 1.92ac 16.4 ± 5.59ab 12.2 ± 1.92c
 Day 11 7.4 ± 1.34 16.4 ± 3.05 18.0 ± 3.16a 33.8 ± 5.54abc 42.4 ± 6.69abc 25.0 ± 4.12ae
 Day 30 7.4 ± 1.14 36.0 ± 2.91a 29.6 ± 2.88ab 25.8 ± 2.95ab 26.2 ± 3.03ab 34.4 ± 3.05ade
OSOM
 Day 4 6.0 ± 1.58 6.8 ± 1.92 22.2 ± 2.28ab 21.6 ± 2.40ab 23.4 ± 3.64ab 14.8 ± 3.96abcde
 Day 7 8.0 ± 1.58 12.4 ± 2.07 29.6 ± 1.67ab 30.0 ± 3.16ab 23.4 ± 7.30 21.8 ± 2.86abc
 Day 11 7.0 ± 1.58 13.8 ± 2.86 29.6 ± 5.55ab 26.8 ± 3.27ab 26.2 ± 2.38ab 23.6 ± 3.84ab
 Day 30 6.8 ± 0.83 37.4 ± 5.27a 30.6 ± 7.92a 31.6 ± 2.70a 25.0 ± 4.12a 37.6 ± 3.64ae
  1. Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Bonferroni post hoc for multiple comparisons
  2. HPF high power field, OSOM outer strip of outer medulla, rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium
  3. aSignificant difference vs. negative control group bSignificant difference vs. cisplatin-treated group cSignificant difference vs. cisplatin + rBMSCs-treated group dSignificant difference vs. cisplatin + hADSCs-treated group eSignificant difference vs. cisplatin + hAFSCs-treated group